Genetic dissection of down syndrome-associated alterations in APP/amyloid-β biology using mouse models
Individuals who have Down syndrome (caused by trisomy of chromosome 21), have a greatly elevated risk of early-onset Alzheimer’s disease, in which amyloid-β accumulates in the brain. Amyloid-β is a product of the chromosome 21 gene APP (amyloid precursor protein) and the extra copy or ‘dose’ of APP...
Saved in:
Published in | Scientific reports Vol. 11; no. 1; pp. 5736 - 13 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
11.03.2021
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Individuals who have Down syndrome (caused by trisomy of chromosome 21), have a greatly elevated risk of early-onset Alzheimer’s disease, in which amyloid-β accumulates in the brain. Amyloid-β is a product of the chromosome 21 gene
APP
(amyloid precursor protein) and the extra copy or ‘dose’ of
APP
is thought to be the cause of this early-onset Alzheimer’s disease. However, other chromosome 21 genes likely modulate disease when in three-copies in people with Down syndrome. Here we show that an extra copy of chromosome 21 genes, other than
APP
, influences APP/Aβ biology. We crossed Down syndrome mouse models with partial trisomies, to an
APP
transgenic model and found that extra copies of subgroups of chromosome 21 gene(s) modulate amyloid-β aggregation and
APP
transgene-associated mortality, independently of changing amyloid precursor protein abundance. Thus, genes on chromosome 21, other than
APP,
likely modulate Alzheimer’s disease in people who have Down syndrome. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-021-85062-3 |